Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy

Oncogene volume 39, pages 7106–7113 (2020)Cite this article

Subjects

Abstract

Cancer immunotherapy using immune-checkpoint blockade has displayed promising clinical effects, but prevalent antibody-based inhibitors face multiple challenges such as low response rate, acquired resistance, and adverse effects. The intracellular expression of PD-1/PD-L1 in recycling endosomes and their active trafficking to membrane highlight the importance of depleting rather than interfering with checkpoint proteins. Preclinical investigations on the therapeutic effects of lead compounds that function by degrading immune checkpoint ligands and receptors have reported highly promising results. By harnessing the degradation capabilities of the lysosome, proteasome and autophagosomes, different small molecules and peptides potently induced degradation of checkpoint proteins and enhanced anti-tumor immunity. Both in vitro and in vivo experiments support the therapeutic efficacy of these molecules. Thus, targeted degradation through endo-lysosomal, autophagic, proteasomal, or endoplasmic reticulum-related pathways may provide promising strategies for tackling the challenges in cancer immunotherapy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Modes of actions of different targeting molecules.
Fig. 2: Repurposed screening as a promising strategy for discovering immune checkpoint inhibitors.

Similar content being viewed by others

References

  1. Cha JH, Chan LC, Song MS, Hung MC. New approaches on cancer immunotherapy. Cold Spring Harbor perspectives in medicine. 2019;10:a036863.

    Google Scholar 

  2. Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25:656–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Hakenberg OW. Nivolumab for the treatment of bladder cancer. Expert Opin Biol Ther. 2017;17:1309–15.

    CAS  PubMed  Google Scholar 

  4. Greillier L, Tomasini P, Barlesi F. The clinical utility of tumor mutational burden in non-small cell lung cancer. Transl Lung Cancer Res. 2018;7:639–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Esfahani K, Buhlaiga N, Thebault P, Lapointe R, Johnson NA, Miller WH Jr. Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. N Engl J Med. 2019;380:2375–6.

    PubMed  Google Scholar 

  6. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1008–19.

    PubMed  PubMed Central  Google Scholar 

  7. Liu Y, Wang H, Deng J, Sun C, He Y, Zhou C. Toxicity of tumor immune checkpoint inhibitors-more attention should be paid. Transl Lung Cancer Res. 2019;8:1125–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Hsu JM, Li CW, Lai YJ, Hung MC. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. Cancer Res. 2018;78:6349–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell. 2019;76:359–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Chen S, Song Z, Zhang A. Small-molecule immuno-oncology therapy: advances, challenges and new directions. Curr Top Med Chem. 2019;19:180–5.

    CAS  PubMed  Google Scholar 

  11. Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell. 2015;162:1242–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Li H, Li X, Liu S, Guo L, Zhang B, Zhang J, et al. Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology. 2017;66:1920–33.

    CAS  PubMed  Google Scholar 

  14. Pu N, Gao S, Yin H, Li JA, Wu W, Fang Y, et al. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Cancer Lett. 2019;460:42–53.

    CAS  PubMed  Google Scholar 

  15. Theivanthiran B, Evans KS, DeVito NC, Plebanek MP, Sturdivant M, Wachsmuth LP. et al. A tumor-intrinsic PD-L1-NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Investig. 2020;130:2570–86.

    CAS  PubMed  Google Scholar 

  16. Yao H, Wang H, Li C, Fang JY, Xu J. Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. Front Immunol. 2018;9:1774.

    PubMed  PubMed Central  Google Scholar 

  17. Brosseau JP. Regulations on Messenger RNA: Wires and Nodes. Adv Exp Med Biol. 2020;1248:251–63.

    PubMed  Google Scholar 

  18. Wang Y, Deng S, Xu J. Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets. Cancer Biol Med. 2020;17:583–98.

    PubMed  PubMed Central  Google Scholar 

  19. Liang L, Wang H, Shi H, Li Z, Yao H, Bu Z, et al. A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity. Cell Chem Biol. 2018;25:761–.e765.

    CAS  PubMed  Google Scholar 

  20. Sun X, Gao H, Yang Y, He M, Wu Y, Song Y, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019;4:64.

    PubMed  PubMed Central  Google Scholar 

  21. Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion. Front Oncol. 2018;8:386.

    PubMed  PubMed Central  Google Scholar 

  22. Wang H, Yao H, Li C, Shi H, Lan J, Li Z, et al. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat Chem Biol. 2019;15:42–50.

    CAS  PubMed  Google Scholar 

  23. Gao H, Yang Z, Zhang S, Cao S, Shen S, Pang Z, et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep. 2013;3:2534.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Kiran S, Dwivedi P, Khatik R, Hameed S, Dwivedi M, Huang F, et al. Synthesis of a functionalized dipeptide for targeted delivery and pH-sensitive release of chemotherapeutics. Chem Commun (Camb). 2019;56:285–8.

    Google Scholar 

  25. Dua P,SS, Kim S, Lee DK. ALPPL2 Aptamer-Mediated Targeted Delivery of 5-Fluoro-2’-Deoxyuridine to Pancreatic Cancer. Nucleic Acid Ther. 2015;25:180–7.

    CAS  PubMed  Google Scholar 

  26. Lyle C, Richards S, Yasuda K, Napoleon MA, Walker J, Arinze N, et al. c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. Sci Rep. 2019;9:20257.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Meng X, Liu X, Guo X, Jiang S, Chen T, Hu Z, et al. FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature. 2018;564:130–5.

    CAS  PubMed  Google Scholar 

  28. Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91–95.

    CAS  PubMed  Google Scholar 

  29. Jingjing W, Wenzheng G, Donghua W, Guangyu H, Aiping Z, Wenjuan W. Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma. Cancer Med. 2018;7:4004–11.

    PubMed  PubMed Central  Google Scholar 

  30. Yao H, Xu J. Regulation of Cancer Immune Checkpoint: Mono- and Poly-Ubiquitination: Tags for Fate. Adv Exp Med Biol. 2020;1248:295–324.

    PubMed  Google Scholar 

  31. Delport A, Hewer R. Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules. Molecules. 2019;24:3272.

    PubMed Central  Google Scholar 

  32. Wang Y, Jiang X, Feng F, Liu W, Sun H. Degradation of proteins by PROTACs and other strategies. Acta Pharm Sin B. 2020;10:207–38.

    PubMed  Google Scholar 

  33. Neklesa T, Snyder LB, Willard RR, Vitale N, Pizzano J, Gordon DA, et al. ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer. J Clin Oncol. 2019;37:259–259.

    Google Scholar 

  34. Dvela-Levitt M, Kost-Alimova M, Emani M, Kohnert E, Thompson R, Sidhom EH, et al. Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy. Cell. 2019;178:521–35 e523.

    CAS  PubMed  Google Scholar 

  35. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, et al. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018;71:606–20 e607.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Verdura S, Cuyàs E, Cortada E, Brunet J, Lopez-Bonet E, Martin-Castillo B, et al. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging (Albany NY). 2020;12:8–34.

    CAS  Google Scholar 

  37. Wei Z, Zhang M, Li C, Huang W, Fan Y, Guo J, et al. Specific TBC Domain-Containing Proteins Control the ER-Golgi-Plasma Membrane Trafficking of GPCRs. Cell Rep. 2019;28:554–66 e554.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Gomez-Navarro N, Miller E. Protein sorting at the ER-Golgi interface. J Cell Biol. 2016;215:769–78.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Wang H, Han X, Xu J. Lysosome as the Black Hole for Checkpoint Molecules. Adv Exp Med Biol. 2020;1248:325–46.

    PubMed  Google Scholar 

  40. Deng S, Zhou X, Xu J. Checkpoints under traffic control: from and to organelles. Adv Exp Med Biol. 2020;1248:431–53.

    PubMed  Google Scholar 

  41. Greenberg M, DeTulleo L, Rapoport I, Skowronski J, Kirchhausen T. A dileucine motif in HIV-1 Nef is essential for sorting into clathrin-coated pits and for downregulation of CD4. Curr Biol. 1998;8:1239–42.

    CAS  PubMed  Google Scholar 

  42. Riggs NL, Craig HM, Pandori MW, Guatelli JC. The dileucine-based sorting motif in HIV-1 Nef is not required for down-regulation of class I MHC. Virology. 1999;258:203–7.

    CAS  PubMed  Google Scholar 

  43. Steven B, Kayvon P, Simon W, Nicholas R, Carolyn B. Lysosome Targeting Chimeras (LYTACs) for the degradation of secreted and membrane proteins. 2019;584:291–7.

  44. Endicott SJ, Boynton DN, Jr., Beckmann LJ, Miller RA. Long-lived mice with reduced growth hormone signaling have a constitutive upregulation of hepatic chaperone-mediated autophagy. Autophagy. 2020: 1–14.

  45. Fan X, Jin WY, Lu J, Wang J, Wang YT. Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat Neurosci. 2014;17:471–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Valdor R, Garcia-Bernal D, Riquelme D, Martinez CM, Moraleda JM, Cuervo AM, et al. Glioblastoma ablates pericytes antitumor immune function through aberrant up-regulation of chaperone-mediated autophagy. Proc Natl Acad Sci USA. 2019;116:20655–65.

    CAS  PubMed  Google Scholar 

  47. Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy. 2011;7:279–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Wang X, Wu WKK, Gao J, Li Z, Dong B, Lin X, et al. Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res. 2019;38:140.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng. 2019;3:306–17.

    CAS  PubMed  Google Scholar 

  50. Yao H, Li C, Brosseau J-P, Wang H, Lu H, Fang C et al. Palmitoylation is critically required for cancer intrinsic PD-1 expression and functions. bioRxiv. 2019: 625483.

  51. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Disco. 2019;18:41–58.

    CAS  Google Scholar 

  52. Baek K, Schulman BA. Molecular glue concept solidifies. Nat Chem Biol. 2020;16:2–3.

    CAS  PubMed  Google Scholar 

  53. Chamberlain PP, Hamann LG. Development of targeted protein degradation therapeutics. Nat Chem Biol. 2019;15:937–44.

    CAS  PubMed  Google Scholar 

  54. Yang Q, Peng L, Wu Y, Li Y, Wang L, Luo JH, et al. Endocytic adaptor protein HIP1R controls intracellular trafficking of epidermal growth factor receptor in neuronal dendritic development. Front Mol Neurosci. 2018;11:447.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Gao H, Sun X, Rao Y. PROTAC technology: opportunities and challenges. ACS Med Chem Lett. 2020;11:237–40.

    PubMed  Google Scholar 

  56. Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Disco. 2017;16:19–34.

    CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by National Natural Science Foundation of China (No: 82030104, 81874050, 81572326), Basic Research Projects of Shanghai Science and Technology Innovation Action Plan (20JC1410700); National Key R & D Program of China (2016YFC0906002, 2016YFC0906002), Tang Scholar (JX), and Startup Research Funding of Fudan University.

Author information

Authors and Affiliations

  1. Institutes of Biomedical Sciences and Zhongshan-Xuhui Hospital, Key Laboratory of Epigenetics and Metabolism, Fudan University, Shanghai, China

    Jie Xu

  2. Centre de Recherche du Centre Hospitalier de Sherbrooke, Sherbrooke, Canada

    Jean-Philippe Brosseau

  3. Department of Biochemistry and Functional Genomics, Université de Sherbrooke, Sherbrooke, Canada

    Jean-Philippe Brosseau

  4. Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China

    Hubing Shi

Authors
  1. Jie Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Philippe Brosseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hubing Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jie Xu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, J., Brosseau, JP. & Shi, H. Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy. Oncogene 39, 7106–7113 (2020). https://doi.org/10.1038/s41388-020-01491-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-020-01491-w

This article is cited by

Search

Advanced search

Quick links